Short answer
RET tumor testing looks for changes inside the cancer itself, usually to understand tumor biology or treatment options. RET germline testing looks for inherited variants in normal tissue such as blood or saliva and is the test that can clarify MEN2 risk for the patient and relatives. The two tests overlap in name but answer different questions, and a result from one should not be treated as if it came from the other.
Which test is which
| Test type | Sample | Main question | Why it matters |
|---|---|---|---|
| Tumor RET testing | Tumor tissue | Does the cancer carry a RET alteration? | May help with tumor characterization and therapy planning. |
| Germline RET testing | Blood, saliva, or buccal sample | Is a RET variant inherited? | Can change MEN2 surveillance and family testing. |
| Paired tumor-normal testing | Tumor plus normal tissue | Is the result somatic, germline, or both? | Helps separate cancer-biology from inherited-risk questions. |
When each test is ordered
- Tumor testing is often ordered when the cancer report needs a biomarker answer, especially in advanced or recurrent disease.
- Germline testing is often ordered when medullary thyroid cancer, MEN2, family history, or a known familial RET variant raises inherited-risk questions.
- Paired tumor-normal testing is useful when a single tumor finding could be somatic, inherited, or hard to interpret from one specimen alone.
What the result can and cannot tell you
A positive tumor RET finding does not automatically mean the patient has inherited MEN2. A negative germline RET result lowers the chance of hereditary MEN2, but it does not erase the tumor question or guarantee that every relevant RET region was fully covered. That is why report type, specimen type, and the exact variant matter so much before anyone makes a family or treatment decision.
For medullary thyroid cancer, the safest interpretation is to ask whether the report is talking about the tumor, the inherited risk, or both. NCI and GeneReviews both emphasize that those questions are related but not interchangeable.
When family history changes the next step
Follow-up matters more when a tumor RET finding could affect family-risk counseling, or when paired tumor-normal testing is needed to separate inherited risk from cancer-only biology. Genetics counseling helps decide which sample type should drive the next step.
When specialist review matters
Specialist review matters when the report type is still unclear, because tumor-only and germline RET testing answer different questions and should not be used interchangeably.
How genetic testing is done
Genetic testing is usually done with blood or saliva, and the lab workflow depends on whether the question is a targeted variant, a panel, or confirmation after a clinical finding. Genetics counseling can help clarify whether the next step is a new test, family testing, or a different clinical workup.
Questions to ask
- Was the RET result from tumor tissue, blood, saliva, or paired tumor-normal testing?
- Is the report describing a pathogenic variant, likely pathogenic variant, VUS, fusion, or other alteration?
- Did the lab test enough RET regions to answer the question being asked?
- Should a genetics team or endocrine cancer specialist review the family implications?
FAQ
What is the difference between tumor RET testing and germline RET testing?
Tumor RET testing looks at the cancer itself, while germline RET testing looks for an inherited variant in normal tissue such as blood or saliva.
If RET is found in the tumor, does that mean it was inherited?
No. A tumor RET finding can be somatic, so it may be limited to the cancer and not present in the rest of the body.
If germline RET is negative, is the tumor question still open?
Yes. Tumor testing can still matter for cancer biology or treatment even when inherited RET risk looks less likely.
When is paired tumor-normal testing helpful?
It is helpful when you need to separate somatic from inherited findings and do not want to guess from tumor-only data.
Do relatives need testing after a tumor-only RET finding?
Not automatically. Relatives usually need targeted testing only if a germline pathogenic variant or other inherited-risk clue is confirmed.
What should I ask before acting on the result?
Ask which specimen was tested, what exact variant was reported, whether the result is inherited or somatic, and who is coordinating follow-up.
Related guides: negative RET testing with medullary thyroid cancer, positive RET test next steps, medullary thyroid cancer RET result routing, and RET tumor-only vs germline follow-up.